Panna Bhattacharyya, MD
Neurology · Searcy, ARNPI 1396277729
Payments from drug & device makers
Across 484 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$1K
- Novartis$755
- Pfizer$745
- Biogen$592
- SK Life Science, Inc.$582
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,330 |
| UCB, Inc. | 68 | $1,148 |
| Novartis | 38 | $755 |
| Pfizer | 64 | $745 |
| Biogen | 34 | $592 |
| SK Life Science, Inc. | 26 | $582 |
| Amgen | 20 | $412 |
| Lundbeck LLC | 22 | $353 |
| Amneal Pharmaceuticals LLC | 19 | $313 |
| AstraZeneca | 16 | $296 |
| Neurocrine Biosciences, Inc. | 11 | $202 |
| Eisai Inc. | 8 | $178 |
| Genentech USA, Inc. | 9 | $163 |
| Neurelis, Inc. | 8 | $163 |
| Kyowa Kirin, Inc. | 8 | $162 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $153 |
| Mallinckrodt Hospital Products Inc. | 5 | $124 |
| Lilly USA, LLC | 8 | $116 |
| Livanova USA, Inc. | 2 | $108 |
| TG Therapeutics, Inc. | 4 | $88 |
| Tanabe Pharma America, Inc. | 6 | $86 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Corium, LLC | 5 | $60 |
| Bristol Myers Squibb | 3 | $56 |
| Medtronic | 2 | $54 |
| Argenx US, Inc. | 2 | $49 |
| Sanofi | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Springworks Therapeutics, Inc. | 1 | $28 |
| Boston Scientific | 1 | $27 |
| Johnson & Johnson | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| CSL Behring | 1 | $22 |
| GE HealthCare | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$8,566 in reported general payments places this provider in the 60th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 56 | $84,049 |
| QuliptaAtogepant | 42 | $47,976 |
| UbrelvyUbrogepant | 26 | $37,334 |
| Emgality PenGalcanezumab-Gnlm | 36 | $24,581 |
| XcopriCenobamate | 12 | $13,653 |
| Gabapentin | 358 | $3,591 |
| Pyridostigmine Bromide | 43 | $3,425 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 139 | $3,305 |
| Levetiracetam | 134 | $2,849 |
| Duloxetine Hcl | 144 | $2,643 |
| Primidone | 187 | $2,328 |
| Pregabalin | 133 | $2,043 |
| Memantine Hcl | 110 | $2,012 |
| Lacosamide | 18 | $1,436 |
| Donepezil Hcl | 241 | $1,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,330 | $85,30968 claims |
| PfizerNurtec Odt | $745 | $84,04956 claims |
| SK Life Science, Inc.Xcopri | $582 | $13,65312 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $313 | $3,42543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 93 neurology providers in Arkansas.
Other neurology in Searcy
- Michael ClevengerSearcy$8K
- Shari DesilvaRogers$5.7M
- Steve-Felix BelingaFort Smith$809K
- Richard PellegrinoHot Springs$573K
- Kathryn ChenaultSherwood$532K
- Kapil AryaLittle Rock$405K
- Margaret TremwelFayetteville$261K
- Michael MorseFayetteville$149K
- Mark PippengerNorth Little Rock$109K
- Gordon GibsonHot Springs,$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.